Results 171 to 180 of about 152,115 (284)

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

Cost-effectiveness analysis of toripalimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma. [PDF]

Front Public Health
Wu C, Wei T, Ye X, Dong Z, Chen X.
europepmc   +1 more source

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park, Shihyun Kim, Seo‐Yeong An, Reuben H. Kim, Jongho Choi, Moon‐Young Kim   +5 more
wiley   +1 more source

Phase II study of maintenance trifluridine/tipiracil (TAS-102) plus bevacizumab after induction chemotherapy in metastatic colorectal cancer. [PDF]

Oncologist
Ota K, Uemura M, Tanida T, Nakata K, Kudo T, Kagawa Y, Haraguchi N, Minami S, Matsuura Y, Ota H, Hiraki M, Yasui M, Takahashi H, Iwamoto K, Nishida N, Hata T, Nishizawa Y, Fukunaga M, Komori T, Takahashi Y, Tokuyama S, Tamagawa H, Naito A, Yoshihara T, Suzuki R, Sugimoto S, Miyake M, Takiguchi N, Tei M, Tamai K, Fukada A, Ogino T, Miyoshi N, Satoh T, Yamamoto H, Murata K, Doki Y, Eguchi H.   +37 more
europepmc   +1 more source

The role of extracellular vesicles in cell–cell crosstalk in cardiotoxicity

The Journal of Physiology, EarlyView.
Abstract figure legend Administration of a pharmacological agent can result in off‐target cardiotoxicity which can be driven by cell–cell crosstalk between healthy and dysfunctional cardiac cells. Extracellular vesicles (EVs) are lipid bilayer structures that can move biological cargo between cells, facilitating cell–cell crosstalk.
Gabriella Bachynskyj‐Bilas, Debbie J. Otto, Daniel Stratton, Katja Rietdorf, Daniel M. Johnson, Calum J. McMullen   +5 more
wiley   +1 more source

Intravitreal Bevacizumab plus Methotrexate for iris and ciliary body metastasis from lung cancer. [PDF]

Am J Ophthalmol Case Rep
Bastos TMA, Coelho IN, Audi L, Chahud F, Folgosa M, Correa ZM, Jorge R.   +6 more
europepmc   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study. [PDF]

Signal Transduct Target Ther
Yang W, Zhang J, Liang P, Qian Z, Wang D, Zhang W, Li B, Cui C, Zhong X, Wu G, Sun Y.   +10 more
europepmc   +1 more source

Detection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite‐unstable gastrointestinal cancers: A pilot study

International Journal of Cancer, Volume 158, Issue 12, Page 3312-3323, 15 June 2026.
What's new? A substantial proportion of patients with microsatellite‐unstable gastrointestinal adenocarcinomas do not benefit from immunotherapy. This study demonstrates that microsatellite instability can be reliably detected in plasma‐derived extracellular vesicle DNA from patients with microsatellite‐unstable gastrointestinal cancers.
Aysel Ahadova, Lena Bohaumilitzky, Thomas Walle, Joscha A. Kraske, Mirjam Tariverdian, Ulrike Ganserer‐Schmitt, Ingrid Hausser‐Siller, Vera Fuchs, Nina Nelius, Gizem Mehtap Erisen, Johannes Gebert, Albrecht Stenzinger, Dirk Jäger, Magnus von Knebel Doeberitz, Georg Martin Haag, Elena Busch, Matthias Kloor   +16 more
wiley   +1 more source

Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab. [PDF]

Radiol Oncol
Popovic P, Kalamutova A, Djokic M, Cuderman A, Boltezar G, Trotovsek B.   +5 more
europepmc   +1 more source